$5.41
0.37%
Nasdaq, Jul 03, 10:54 pm CET
ISIN
US92764N1028
Symbol
VIR

Vir Biotechnology Inc Target price 2025 - Analyst rating & recommendation

Vir Biotechnology Inc Classifications & Recommendation:

Buy
77%
Hold
23%

Vir Biotechnology Inc Price Target

Target Price $16.32
Price $5.41
Potential
Number of Estimates 9
9 Analysts have issued a price target Vir Biotechnology Inc 2026 . The average Vir Biotechnology Inc target price is $16.32. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 10 Analysts recommend Vir Biotechnology Inc to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Vir Biotechnology Inc stock has an average upside potential 2026 of . Most analysts recommend the Vir Biotechnology Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 74.21 16.54
13.89% 77.72%
EBITDA Margin -743.66% -3,210.26%
6.28% 331.68%
Net Margin -703.36% -2,700.60%
1.45% 283.96%

10 Analysts have issued a sales forecast Vir Biotechnology Inc 2025 . The average Vir Biotechnology Inc sales estimate is

$16.5m
Unlock
. This is
20.72% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$71.4m 242.28%
Unlock
, the lowest is
$2.9m 85.91%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $74.2m 13.89%
2025
$16.5m 77.72%
Unlock
2026
$16.4m 0.77%
Unlock
2027
$24.1m 46.71%
Unlock
2028
$118m 392.02%
Unlock
2029
$181m 52.91%
Unlock
2030
$256m 41.17%
Unlock

7 Analysts have issued an Vir Biotechnology Inc EBITDA forecast 2025. The average Vir Biotechnology Inc EBITDA estimate is

$-531m
Unlock
. This is
11.33% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-440m 26.47%
Unlock
, the lowest is
$-608m 1.49%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-552m 19.29%
2025
$-531m 3.80%
Unlock
2026
$-535m 0.81%
Unlock
2027
$-527m 1.56%
Unlock
2028
$-360m 31.69%
Unlock
2029
$-304m 15.63%
Unlock
2030
$-180m 40.59%
Unlock

EBITDA Margin

2024 -743.66% 6.28%
2025
-3,210.26% 331.68%
Unlock
2026
-3,261.57% 1.60%
Unlock
2027
-2,188.32% 32.91%
Unlock
2028
-303.81% 86.12%
Unlock
2029
-167.63% 44.82%
Unlock
2030
-70.55% 57.91%
Unlock

10 Vir Biotechnology Inc Analysts have issued a net profit forecast 2025. The average Vir Biotechnology Inc net profit estimate is

$-447m
Unlock
. This is
22.69% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-360m 37.76%
Unlock
, the lowest is
$-551m 4.67%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-522m 15.14%
2025
$-447m 14.44%
Unlock
2026
$-430m 3.68%
Unlock
2027
$-390m 9.44%
Unlock
2028
$-231m 40.70%
Unlock
2029
$-281m 21.63%
Unlock
2030
$-117m 58.31%
Unlock

Net Margin

2024 -703.36% 1.45%
2025
-2,700.60% 283.96%
Unlock
2026
-2,621.48% 2.93%
Unlock
2027
-1,618.19% 38.27%
Unlock
2028
-195.03% 87.95%
Unlock
2029
-155.13% 20.46%
Unlock
2030
-45.81% 70.47%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.83 -3.23
16.56% 15.67%
P/E negative
EV/Sales negative

10 Analysts have issued a Vir Biotechnology Inc forecast for earnings per share. The average Vir Biotechnology Inc EPS is

$-3.23
Unlock
. This is
23.10% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-2.60 38.10%
Unlock
, the lowest is
$-3.99 5.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.83 16.56%
2025
$-3.23 15.67%
Unlock
2026
$-3.12 3.41%
Unlock
2027
$-2.82 9.62%
Unlock
2028
$-1.67 40.78%
Unlock
2029
$-2.04 22.16%
Unlock
2030
$-0.85 58.33%
Unlock

P/E ratio

Current -1.29 42.40%
2025
-1.67 29.65%
Unlock
2026
-1.74 4.19%
Unlock
2027
-1.92 10.34%
Unlock
2028
-3.23 68.23%
Unlock
2029
-2.66 17.65%
Unlock
2030
-6.38 139.85%
Unlock

Based on analysts' sales estimates for 2025, the Vir Biotechnology Inc stock is valued at an EV/Sales of

-3.25
Unlock
and an P/S ratio of
45.22
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -2.58 435.06%
2025
-3.25 26.07%
Unlock
2026
-3.28 0.78%
Unlock
2027
-2.23 31.84%
Unlock
2028
-0.45 79.68%
Unlock
2029
-0.30 34.60%
Unlock
2030
-0.21 29.16%
Unlock

P/S ratio

Current 35.85 135.55%
2025
45.22 26.14%
Unlock
2026
45.58 0.78%
Unlock
2027
31.07 31.84%
Unlock
2028
6.31 79.68%
Unlock
2029
4.13 34.60%
Unlock
2030
2.93 29.16%
Unlock

Current Vir Biotechnology Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Needham
Locked
Locked
Locked May 22 2025
Needham
Locked
Locked
Locked May 12 2025
Goldman Sachs
Locked
Locked
Locked Apr 17 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 28 2025
Barclays
Locked
Locked
Locked Feb 28 2025
Needham
Locked
Locked
Locked Feb 27 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 31 2025
Analyst Rating Date
Locked
Needham:
Locked
Locked
May 22 2025
Locked
Needham:
Locked
Locked
May 12 2025
Locked
Goldman Sachs:
Locked
Locked
Apr 17 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 28 2025
Locked
Barclays:
Locked
Locked
Feb 28 2025
Locked
Needham:
Locked
Locked
Feb 27 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 31 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today